ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

W. J. Wong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-4446-0576; OpenAlex author ID A5114100307. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-… Co-author DOI 10.1177/17588359261431386 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

F Lee · 1 shared paper, 2026 · strength 0.27
- Paper NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refra… DOI 10.1177/17588359261431386 ↗
Hung-Yuan Yu · 1 shared paper, 2026 · strength 0.27
- Paper NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refra… DOI 10.1177/17588359261431386 ↗
Nai‐Jung Chiang · 1 shared paper, 2026 · strength 0.27
- Paper NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refra… DOI 10.1177/17588359261431386 ↗
Kuei‐Chuan Lee · 1 shared paper, 2026 · strength 0.27
- Paper NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refra… DOI 10.1177/17588359261431386 ↗
Chung‐Pin Li · 1 shared paper, 2026 · strength 0.27
- Paper NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refra… DOI 10.1177/17588359261431386 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.